Recruiting | Phase II
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients.
To find out the effects, good and/or bad, of adding the study agent ramucirumab to the usual chemotherapy regimen.
- Arm A will receive the usual treatment mFOLFIRINOX plus the study agent ramucirumab.
- Arm B:will receive the usual treatment mFOLFIRINOX plus a placebo.
Key Participation Requirements:
Female or Male
19 years and older
Advanced pancreatic adenocarcinoma cancer that has spread to other parts of your body
No prior treatment for metastatic or recurrent disease.
Chemotherapy and/or radiation given before or after surgery with disease that has grown after 6 months is allowed.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.
To learn more about this clinical trial please contact us today!